Research programme: antibacterials - Achillion/FOB SynthesisAlternative Names: FSI-1297; FSI-1671; FSI-1686
Latest Information Update: 25 Jun 2013
At a glance
- Originator FOB Synthesis
- Developer Achillion Pharmaceuticals; FOB Synthesis
- Class Carbapenems
- Mechanism of Action Cell wall inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bacterial infections